Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1939 1
1946 2
1947 5
1948 1
1950 1
1951 2
1953 1
1955 2
1957 1
1958 1
1959 1
1960 3
1961 1
1963 3
1965 3
1966 3
1967 2
1968 8
1969 2
1970 4
1971 8
1972 13
1973 11
1974 8
1975 49
1976 94
1977 91
1978 101
1979 98
1980 147
1981 172
1982 209
1983 263
1984 318
1985 389
1986 438
1987 564
1988 549
1989 666
1990 874
1991 866
1992 902
1993 1102
1994 1187
1995 1259
1996 1464
1997 1550
1998 1648
1999 1778
2000 1875
2001 1881
2002 2077
2003 2320
2004 2406
2005 2724
2006 2813
2007 2797
2008 2969
2009 3106
2010 3543
2011 3901
2012 4147
2013 4235
2014 4586
2015 4759
2016 4767
2017 5100
2018 5186
2019 5602
2020 6330
2021 7054
2022 6879
2023 6434
2024 2337

Text availability

Article attribute

Article type

Publication date

Search Results

103,043 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for dose median
Search for Jose Melian instead (2 results)
High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network.
Hermine O, Jiang L, Walewski J, Bosly A, Thieblemont C, Szymczyk M, Pott C, Salles G, Feugier P, Hübel K, Haioun C, Casasnovas RO, Schmidt C, Bouabdallah K, Ribrag V, Kanz L, Dürig J, Metzner B, Sibon D, Cheminant M, Burroni B, Klapper W, Hiddemann W, Unterhalt M, Hoster E, Dreyling M; European Mantle Cell Lymphoma Network. Hermine O, et al. J Clin Oncol. 2023 Jan 20;41(3):479-484. doi: 10.1200/JCO.22.01780. Epub 2022 Dec 5. J Clin Oncol. 2023. PMID: 36469833 Clinical Trial.
After a median follow-up of 10.6 years, the time to treatment failure was still significantly improved in the R-DHAP versus R-CHOP arms (medians 8.4 v 3.9 years, 5-/10-year rates 64%/46% v 41%/25%, P = .038, hazard ratio, 0.59). Median overall survival (OS) w …
After a median follow-up of 10.6 years, the time to treatment failure was still significantly improved in the R-DHAP versus R-CHOP ar …
Effect of Reduced Exposure to Vasopressors on 90-Day Mortality in Older Critically Ill Patients With Vasodilatory Hypotension: A Randomized Clinical Trial.
Lamontagne F, Richards-Belle A, Thomas K, Harrison DA, Sadique MZ, Grieve RD, Camsooksai J, Darnell R, Gordon AC, Henry D, Hudson N, Mason AJ, Saull M, Whitman C, Young JD, Rowan KM, Mouncey PR; 65 trial investigators. Lamontagne F, et al. JAMA. 2020 Mar 10;323(10):938-949. doi: 10.1001/jama.2020.0930. JAMA. 2020. PMID: 32049269 Free PMC article. Clinical Trial.
Patients randomized to the permissive hypotension group had lower exposure to vasopressors compared with those in the usual care group (median duration 33 hours vs 38 hours; difference in medians, -5.0; 95% CI, -7.8 to -2.2 hours; total dose in norepinephrine …
Patients randomized to the permissive hypotension group had lower exposure to vasopressors compared with those in the usual care group (m …
Emicizumab for the treatment of acquired hemophilia A.
Knoebl P, Thaler J, Jilma P, Quehenberger P, Gleixner K, Sperr WR. Knoebl P, et al. Blood. 2021 Jan 21;137(3):410-419. doi: 10.1182/blood.2020006315. Blood. 2021. PMID: 32766881 Free article.
Here, we report on 6 male and 6 female patients with AHA treated with emicizumab (all data medians and interquartile range), age 74 (64-80) years, initial FVIII <1%; inhibitor titer 22.3 Bethesda units (BU)/mL (range, 3-2000). ...FVIII (bovine reagents) exceeded 50%, in …
Here, we report on 6 male and 6 female patients with AHA treated with emicizumab (all data medians and interquartile range), age 74 ( …
Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1).
Mi JQ, Zhao W, Jing H, Fu W, Hu J, Chen L, Zhang Y, Yao D, Chen D, Schecter JM, Yang F, Tian X, Sun H, Zhuang SH, Ren J, Fan X, Jin J, Niu T, Chen SJ. Mi JQ, et al. J Clin Oncol. 2023 Feb 20;41(6):1275-1284. doi: 10.1200/JCO.22.00690. Epub 2022 Oct 21. J Clin Oncol. 2023. PMID: 36269898 Clinical Trial.
RESULTS: As of the clinical cutoff of July 19, 2021, 48 patients received a cilta-cel infusion. At an 18-month median follow-up, the overall response rate was 89.6% (95% CI, 77.3 to 96.5), with a median time to first response of approximately 1 month; 77.1% of patie …
RESULTS: As of the clinical cutoff of July 19, 2021, 48 patients received a cilta-cel infusion. At an 18-month median follow-up, the …
Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.
Forbes CA, Worthy G, Harker J, Kleijnen J, Kutikova L, Zelek L, Van Belle S. Forbes CA, et al. Clin Ther. 2014 Apr 1;36(4):594-610. doi: 10.1016/j.clinthera.2014.02.007. Epub 2014 Mar 18. Clin Ther. 2014. PMID: 24656152 Free article. Review.
Darbepoetin alfa patients appeared to need fewer dose increases compared with short-acting ESAs (pooled, 0.75%; I(2) = 21% vs median 26.6% [range, 7.6%-44.6%]) and more dose decreases (median, 74% [range, 57%-75%] vs 22% [range, 2.8%-59%]). A similar p …
Darbepoetin alfa patients appeared to need fewer dose increases compared with short-acting ESAs (pooled, 0.75%; I(2) = 21% vs medi …
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial.
Paz-Ares L, Spira A, Raben D, Planchard D, Cho BC, Özgüroğlu M, Daniel D, Villegas A, Vicente D, Hui R, Murakami S, Spigel D, Senan S, Langer CJ, Perez BA, Boothman AM, Broadhurst H, Wadsworth C, Dennis PA, Antonia SJ, Faivre-Finn C. Paz-Ares L, et al. Ann Oncol. 2020 Jun;31(6):798-806. doi: 10.1016/j.annonc.2020.03.287. Epub 2020 Mar 21. Ann Oncol. 2020. PMID: 32209338 Free PMC article.
Treatment-effect hazard ratios (HRs) were estimated from unstratified Cox proportional hazards models (Kaplan-Meier-estimated medians). RESULTS: In total, 713 patients were randomly assigned, 709 of whom received at least 1 dose of study treatment durvalumab (n = 47 …
Treatment-effect hazard ratios (HRs) were estimated from unstratified Cox proportional hazards models (Kaplan-Meier-estimated medians …
Dose-response relationships of sarcopenia parameters with incident disability and mortality in older Japanese adults.
Seino S, Kitamura A, Abe T, Taniguchi Y, Murayama H, Amano H, Nishi M, Nofuji Y, Yokoyama Y, Narita M, Shinkai S, Fujiwara Y. Seino S, et al. J Cachexia Sarcopenia Muscle. 2022 Apr;13(2):932-944. doi: 10.1002/jcsm.12958. Epub 2022 Feb 25. J Cachexia Sarcopenia Muscle. 2022. PMID: 35212170 Free PMC article.
BACKGROUND: Sarcopenia-related parameters may have differential impacts on health-related outcomes in older adults. We examined dose-response relationships of body composition, muscle strength, and physical performance with incident disability and mortality. ...FMI did not …
BACKGROUND: Sarcopenia-related parameters may have differential impacts on health-related outcomes in older adults. We examined dose- …
Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial.
Kim TW, Bedard PL, LoRusso P, Gordon MS, Bendell J, Oh DY, Ahn MJ, Garralda E, D'Angelo SP, Desai J, Hodi FS, Wainberg Z, Delord JP, Cassier PA, Cervantes A, Gil-Martin M, Wu B, Patil NS, Jin Y, Hoang T, Mendus D, Wen X, Meng R, Cho BC. Kim TW, et al. JAMA Oncol. 2023 Nov 1;9(11):1574-1582. doi: 10.1001/jamaoncol.2023.3867. JAMA Oncol. 2023. PMID: 37768658 Free PMC article.
Counts and percentages are used for categorical variables, and medians and ranges are used for continuous variables. RESULTS: Among the phase 1a (n = 24) and 1b (n = 49) dose-escalation cohorts, the median age was 60 (range, 40-77) and 54 (range, 25-81) years …
Counts and percentages are used for categorical variables, and medians and ranges are used for continuous variables. RESULTS: Among t …
Blood transfusions in mass casualty events: recent trends.
Ramsey G. Ramsey G. Vox Sang. 2020 Jul;115(5):358-366. doi: 10.1111/vox.12916. Epub 2020 Apr 6. Vox Sang. 2020. PMID: 32253763 Review.
RESULTS: Thirty-two MCEs met analysis criteria. Event-wide reports used medians [interquartile ranges] of 1.8 [1.2-3.9] RBC, 0.6 [0.3-0.9] plasma and 0.14 [0.06-0.26] platelet-dose UPA. Trauma centres transfused 3.4 [2.7-6.3] RBC, 2.4 [1.3-4.1] plasma and 0.41 [0.34 …
RESULTS: Thirty-two MCEs met analysis criteria. Event-wide reports used medians [interquartile ranges] of 1.8 [1.2-3.9] RBC, 0.6 [0.3 …
Relationship of Urethral Dose and Genitourinary Toxicity Among Patients Receiving Vaginal High Dose Rate Interstitial Brachytherapy.
Cozma AI, Martell K, Ravi A, Barnes E, Donovan E, Paudel M, Leung E, Taggar A. Cozma AI, et al. Clin Oncol (R Coll Radiol). 2021 Dec;33(12):773-779. doi: 10.1016/j.clon.2021.05.006. Epub 2021 Jun 4. Clin Oncol (R Coll Radiol). 2021. PMID: 34092463
Receiver operator curve analysis was used to define the urethral threshold dose that correlated to genitourinary toxicity. RESULTS: The median age and follow-up times were 67 years (59-75) and 25 months (16-37), respectively. ...Twenty-four of 79 (30%) patients expe …
Receiver operator curve analysis was used to define the urethral threshold dose that correlated to genitourinary toxicity. RESULTS: T …
103,043 results
You have reached the last available page of results. Please see the User Guide for more information.